Multiple Sclerosis, Acute Relapsing Clinical Trial
Official title:
A Double-Blind, Placebo-Controlled, Single Ascending Dose Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse
This is a Phase 1, multi-center, double-blind, randomized, placebo-controlled, dose-escalation study in subjects with relapsing Multiple Sclerosis (MS). The primary outcome will be the safety and tolerability of a single dose of rHIgM22 in relapsing MS subjects.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04546698 -
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
|
||
Completed |
NCT01442233 -
Plasma Exchanges in Multiple Sclerosis (MS) Relapses
|
Phase 3 | |
Temporarily not available |
NCT02606929 -
Use of Well Known Drugs for New Destination - MS Improvement (MSNT)
|
Phase 0 | |
Completed |
NCT02632591 -
Use on Human Beings of Mix of Known Drugs for New Destination - MS Treatment
|
Phase 1 |